HU-308

HU-308
(IUPAC) ime
	[(1R,2R,5R)-2-[2,6-dimetoksi-4-(2-metiloktan-2-il)fenil]-7,7-dimetil-4-biciklo[3.1.1]hept-3-enil] metanol
Klinički podaci
Identifikatori
CAS broj	256934-39-1
ATC kod	nije dodeljen
PubChem	5311172
Hemijski podaci
Formula	C27H43O2
Mol. masa	414,621 g/mol
SMILES	eMolekuli & PubHem
InChI
	InChI=1S/C27H42O3/c1-8-9-10-11-12-26(2,3)19-14-23(29-6)25(24(15-19)30-7)20-13-18(17-28)21-16-22(20)27(21,4)5/h13-15,20-22,28H,8-12,16-17H2,1-7H3 ; Key: CFMRIVODIXTERW-UHFFFAOYSA-N
Farmakoinformacioni podaci
Trudnoća	?
Pravni status	Legal

HU-308 je lek koji deluje kao kanabinoidni agonist. On je visoko selektivan za CB₂ receptora, sa selektivnošću od preko 5000 puta.^[3] Sinteza i karakterizacija ovog liganda su se odvile tokom 1990-tih. On ima analgetsko dejstvo,^[4] promoviše proliferaciju neuronskih matičnih ćelija,^[5] i štiti jetru i krvne sudove od oksidativnog stresa putem inhibicije TNF-α.^[6]^[7]

Reference

↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑ Hanus, L.; Breuer, A.; Tchilibon, S.; Shiloah, S.; Goldenberg, D.; Horowitz, M.; Pertwee, R.; Ross, R. i dr.. (1999). „HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor”. Proceedings of the National Academy of Sciences of the United States of America 96 (25): 14228–14233. Bibcode 1999PNAS...9614228H. DOI:10.1073/pnas.96.25.14228. PMC 24419. PMID 10588688.
↑ Labuda, C.; Koblish, M.; Little, P. (2005). „Cannabinoid CB2 receptor agonist activity in the hindpaw incision model of postoperative pain”. European Journal of Pharmacology 527 (1–3): 172–174. DOI:10.1016/j.ejphar.2005.10.020. PMID 16316653.
↑ Palazuelos, J.; Aguado, T.; Egia, A.; Mechoulam, R.; Guzmán, M.; Galve-Roperh, I. (2006). „Non-psychoactive CB2 cannabinoid agonists stimulate neural progenitor proliferation”. The FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20 (13): 2405–2407. DOI:10.1096/fj.06-6164fje. PMID 17015409.
↑ Rajesh, M.; Pan, H.; Mukhopadhyay, P.; Bátkai, S.; Osei-Hyiaman, D.; Haskó, G.; Liaudet, L.; Gao, B. i dr.. (2007). „Pivotal Advance: Cannabinoid-2 receptor agonist HU-308 protects against hepatic ischemia/reperfusion injury by attenuating oxidative stress, inflammatory response, and apoptosis”. Journal of leukocyte biology 82 (6): 1382–1389. DOI:10.1189/jlb.0307180. PMC 2225476. PMID 17652447.
↑ Rajesh, M.; Mukhopadhyay, P.; Bátkai, S.; Haskó, G.; Liaudet, L.; Huffman, J.; Csiszar, A.; Ungvari, Z. i dr.. (2007). „CB2-receptor stimulation attenuates TNF-α-induced human endothelial cell activation, transendothelial migration of monocytes, and monocyte-endothelial adhesion”. American journal of physiology. Heart and circulatory physiology 293 (4): H2210–H2218. DOI:10.1152/ajpheart.00688.2007. PMC 2229632. PMID 17660390.

Povezano

Spoljašnje veze

	Portal Medicina
	Portal Hemija

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit

[2] Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.

[3] Hanus, L.; Breuer, A.; Tchilibon, S.; Shiloah, S.; Goldenberg, D.; Horowitz, M.; Pertwee, R.; Ross, R. i dr.. (1999). „HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor”. Proceedings of the National Academy of Sciences of the United States of America 96 (25): 14228–14233. Bibcode 1999PNAS...9614228H. DOI:10.1073/pnas.96.25.14228. PMC 24419. PMID 10588688.

[4] Labuda, C.; Koblish, M.; Little, P. (2005). „Cannabinoid CB2 receptor agonist activity in the hindpaw incision model of postoperative pain”. European Journal of Pharmacology 527 (1–3): 172–174. DOI:10.1016/j.ejphar.2005.10.020. PMID 16316653.

[5] Palazuelos, J.; Aguado, T.; Egia, A.; Mechoulam, R.; Guzmán, M.; Galve-Roperh, I. (2006). „Non-psychoactive CB2 cannabinoid agonists stimulate neural progenitor proliferation”. The FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20 (13): 2405–2407. DOI:10.1096/fj.06-6164fje. PMID 17015409.

[6] Rajesh, M.; Pan, H.; Mukhopadhyay, P.; Bátkai, S.; Osei-Hyiaman, D.; Haskó, G.; Liaudet, L.; Gao, B. i dr.. (2007). „Pivotal Advance: Cannabinoid-2 receptor agonist HU-308 protects against hepatic ischemia/reperfusion injury by attenuating oxidative stress, inflammatory response, and apoptosis”. Journal of leukocyte biology 82 (6): 1382–1389. DOI:10.1189/jlb.0307180. PMC 2225476. PMID 17652447.

[7] Rajesh, M.; Mukhopadhyay, P.; Bátkai, S.; Haskó, G.; Liaudet, L.; Huffman, J.; Csiszar, A.; Ungvari, Z. i dr.. (2007). „CB2-receptor stimulation attenuates TNF-α-induced human endothelial cell activation, transendothelial migration of monocytes, and monocyte-endothelial adhesion”. American journal of physiology. Heart and circulatory physiology 293 (4): H2210–H2218. DOI:10.1152/ajpheart.00688.2007. PMC 2229632. PMID 17660390.

[1]